PT-141

PT-141, also known as Bremelanotide, is a peptide studied for its role in signaling pathways tied to desire and motivation. Research focuses on central melanocortin receptors rather than on the vascular system. Bremelanotide has been the subject of multiple reviews and a clinical development program, and published literature describes its regulatory approval for hypoactive sexual desire disorder. CoreX supplies PT-141 for laboratory research use only.

Research describes PT-141 as an agonist at melanocortin receptors in the central nervous system. These receptors are associated with motivation and arousal circuits. Rather than acting directly on circulation, the peptide is studied for influence on neural signaling that sits upstream of vascular response. This central, non-vascular mechanism is the main feature distinguishing it in the research literature on sexual-health pathways.

The most extensively studied area is hypoactive sexual desire disorder in women, which is the subject of several reviews and a phase 3 clinical program. Published reviews cover its physiology, assessment context, and clinical development history, including its first regulatory approval in 2019. Earlier work, including a 2004 review under the PT-141 name, examined its development as an investigational compound acting through central melanocortin signaling.

The safety profile of Bremelanotide has been analyzed across its clinical development program, including phase 3 randomized controlled trials, and that analysis is the primary published reference for adverse events. Specific adverse event rates are not summarized here. Safety data outside the approved clinical indication, including in research settings with different protocols, are limited, and findings from the clinical program should not be assumed to apply to every context.

Research protocols have used 500 to 2,000 mcg per administration, on an as-needed basis, via the subcutaneous route. These figures describe amounts reported in research settings and are not a recommendation for any individual. Each CoreX order ships with a protocol guide for laboratory reference. Researchers should consult the primary literature for the specific study designs in which these amounts were used.